Amy W Chung1,2, Jenniffer M Mabuka3,4, Bongiwe Ndlovu4, Anna Licht1, Hannah Robinson1, Yathisha Ramlakhan4, Musie Ghebremichael1, Tarylee Reddy5, Philip J R Goulder6, Bruce D Walker1,4, Thumbi Ndung'u1,3,4,7, Galit Alter1. 1. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, MA, USA. 2. Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Australia. 3. KwaZulu-Natal Research Institute for TB and HIV. 4. HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal. 5. Biostatistics Unit, Medical Research Council, Durban, South Africa. 6. Department of Paediatrics, University of Oxford, Oxford OX1 3SY, UK. 7. Max Planck Institute for Infection Biology, Charitéplatz 1, 10117 Berlin, Germany.
Abstract
OBJECTIVE: Postinfection HIV viral control and immune correlates analysis of the RV144 vaccine trial indicate a potentially critical role for Fc receptor-mediated antibody functions. However, the influence of functional antibodies in clade C infection is largely unknown. DESIGN: Plasma samples from 361 chronic subtype C-infected, antiretroviral therapy-naive participants were tested for their HIV-specific isotype and subclass distributions, along with their Fc receptor-mediated functional potential. METHOD: Total IgG, IgG subclasses and IgA binding to p24 clade B/C and gp120 consensus C proteins were assayed by multiplex. Antibody-dependent uptake of antigen-coated beads and Fc receptor-mediated natural killer cell degranulation were evaluated as surrogates for antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC), respectively. RESULTS: p24 IgG1 was the only subclass associated with viral control (P = 0.01), with higher p24-specific ADCP and ADCC responses detected in individuals with high p24 IgG1. Although p24 IgG1 levels were enriched in patients with elevated Gag-specific T-cell responses, these levels remained an independent predictor of low-viral loads (P = 0.04) and high CD4+ cell counts (P = 0.004) after adjusting for Gag-specific T-cell responses and for protective HLA class I alleles. CONCLUSION: p24 IgG1 levels independently predict viral control in HIV-1 clade C infection. Whether these responses contribute to direct antiviral control via the recruited killing of infected cells via the innate immune system or simply mark a qualitatively superior immune response to HIV, is uncertain, but highlights the role of p24-specific antibodies in control of clade C HIV-1 infection.
OBJECTIVE: Postinfection HIV viral control and immune correlates analysis of the RV144 vaccine trial indicate a potentially critical role for Fc receptor-mediated antibody functions. However, the influence of functional antibodies in clade C infection is largely unknown. DESIGN: Plasma samples from 361 chronic subtype C-infected, antiretroviral therapy-naive participants were tested for their HIV-specific isotype and subclass distributions, along with their Fc receptor-mediated functional potential. METHOD: Total IgG, IgG subclasses and IgA binding to p24 clade B/C and gp120 consensus C proteins were assayed by multiplex. Antibody-dependent uptake of antigen-coated beads and Fc receptor-mediated natural killer cell degranulation were evaluated as surrogates for antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC), respectively. RESULTS:p24 IgG1 was the only subclass associated with viral control (P = 0.01), with higher p24-specific ADCP and ADCC responses detected in individuals with high p24 IgG1. Although p24 IgG1 levels were enriched in patients with elevated Gag-specific T-cell responses, these levels remained an independent predictor of low-viral loads (P = 0.04) and high CD4+ cell counts (P = 0.004) after adjusting for Gag-specific T-cell responses and for protective HLA class I alleles. CONCLUSION:p24 IgG1 levels independently predict viral control in HIV-1 clade C infection. Whether these responses contribute to direct antiviral control via the recruited killing of infected cells via the innate immune system or simply mark a qualitatively superior immune response to HIV, is uncertain, but highlights the role of p24-specific antibodies in control of clade C HIV-1 infection.
Authors: Vijaya Madhavi; Bruce D Wines; Janaki Amin; Sean Emery; Ester Lopez; Anthony Kelleher; Rob J Center; P Mark Hogarth; Amy W Chung; Stephen J Kent; Ivan Stratov Journal: J Virol Date: 2017-08-24 Impact factor: 5.103
Authors: J M Andrieu; D Eme; A Venet; C Audroin; J M Tourani; M Stern; D Israel-Biet; K Beldjord; F Driss; P Even Journal: Clin Exp Immunol Date: 1988-07 Impact factor: 4.330
Authors: Kaustuv Banerjee; P J Klasse; Rogier W Sanders; Florencia Pereyra; Elizabeth Michael; Min Lu; Bruce D Walker; John P Moore Journal: AIDS Res Hum Retroviruses Date: 2010-04 Impact factor: 2.205
Authors: Jaclyn K Wright; Zabrina L Brumme; Jonathan M Carlson; David Heckerman; Carl M Kadie; Chanson J Brumme; Bingxia Wang; Elena Losina; Toshiyuki Miura; Fundisiwe Chonco; Mary van der Stok; Zenele Mncube; Karen Bishop; Philip J R Goulder; Bruce D Walker; Mark A Brockman; Thumbi Ndung'u Journal: J Virol Date: 2010-08-11 Impact factor: 5.103
Authors: Amy W Chung; Manu P Kumar; Kelly B Arnold; Wen Han Yu; Matthew K Schoen; Laura J Dunphy; Todd J Suscovich; Nicole Frahm; Caitlyn Linde; Alison E Mahan; Michelle Hoffner; Hendrik Streeck; Margaret E Ackerman; M Juliana McElrath; Hanneke Schuitemaker; Maria G Pau; Lindsey R Baden; Jerome H Kim; Nelson L Michael; Dan H Barouch; Douglas A Lauffenburger; Galit Alter Journal: Cell Date: 2015-11-05 Impact factor: 41.582
Authors: Amy W Chung; Musie Ghebremichael; Hannah Robinson; Eric Brown; Ickwon Choi; Sophie Lane; Anne-Sophie Dugast; Matthew K Schoen; Morgane Rolland; Todd J Suscovich; Alison E Mahan; Larry Liao; Hendrik Streeck; Charla Andrews; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Mark S de Souza; Jaranit Kaewkungwal; Punnee Pitisuttithum; Donald Francis; Nelson L Michael; Jerome H Kim; Chris Bailey-Kellogg; Margaret E Ackerman; Galit Alter Journal: Sci Transl Med Date: 2014-03-19 Impact factor: 17.956
Authors: Nicole L Yates; Hua-Xin Liao; Youyi Fong; Allan deCamp; Nathan A Vandergrift; William T Williams; S Munir Alam; Guido Ferrari; Zhi-yong Yang; Kelly E Seaton; Phillip W Berman; Michael D Alpert; David T Evans; Robert J O'Connell; Donald Francis; Faruk Sinangil; Carter Lee; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Abraham Pinter; Susan Zolla-Pazner; Peter B Gilbert; Gary J Nabel; Nelson L Michael; Jerome H Kim; David C Montefiori; Barton F Haynes; Georgia D Tomaras Journal: Sci Transl Med Date: 2014-03-19 Impact factor: 17.956
Authors: Timon Damelang; Elizabeth H Aitken; Wina Hasang; Ester Lopez; Martin Killian; Holger W Unger; Ali Salanti; Alexis Shub; Elizabeth McCarthy; Katherine Kedzierska; Martha Lappas; Stephen J Kent; Stephen J Rogerson; Amy W Chung Journal: Sci Rep Date: 2021-02-18 Impact factor: 4.379
Authors: Hao D Cheng; Karen G Dowell; Chris Bailey-Kellogg; Brittany A Goods; J Christopher Love; Guido Ferrari; Galit Alter; Johannes Gach; Donald N Forthal; George K Lewis; Kelli Greene; Hongmei Gao; David C Montefiori; Margaret E Ackerman Journal: Retrovirology Date: 2021-10-30 Impact factor: 4.602
Authors: Madeleine F Jennewein; Jennifer Mabuka; Cassidy L Papia; Carolyn M Boudreau; Krista L Dong; Margaret E Ackerman; Thumbi Ndung'u; Galit Alter Journal: Front Immunol Date: 2020-08-07 Impact factor: 7.561